The Technical Analyst
Salarius Pharmaceuticals [SLRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Salarius Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.44% $0.473
America/New_York / 16 apr 2024 @ 09:37
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.04 mill |
| EPS: | -3.84 |
| P/E: | -0.120 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 4.31 mill |
| Avg Daily Volume: | 0.110 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.120 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.395 - 0.551 ( +/- 16.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Arthur David J. | Buy | 20 500 | Stock Option (right to buy) |
| 2024-02-20 | Rosenblum Mark J | Buy | 22 500 | Stock Option (right to buy) |
| 2024-02-20 | Mcvicar William K. | Buy | 20 500 | Stock Option (right to buy) |
| 2024-02-20 | Mccreedy Bruce J Jr. | Buy | 20 500 | Stock Option (right to buy) |
| 2024-02-20 | Lieber Jonathan I | Buy | 20 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 99 transactions |
| Buy: 2 809 420 | Sell: 0 |
Forecast:
11:16 - $0.481
Live Trading Signals (every 1 min)
Forecast
1: 09:46 - $0.484
Forecast 2: 10:36 - $0.481
Forecast 3: 11:16 - $0.481
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.473 (-5.44% ) |
| Volume | 0.0016 mill |
| Avg. Vol. | 0.110 mill |
| % of Avg. Vol | 1.417 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SLRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Last 10 Buy Signals
Latest Press Releases
2024-03-22 16:05:00 - Press Release
Salarius Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Patient enrollment resumed in the investigator-initiated phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers
2024-01-03 08:30:00 - Press Release
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat In Combination With Azacitidine To Treat Hematologic Cancers Resumes Patient Enrollment
Additional ewing sarcoma patient in company's phase 1/2 sarcoma trial achieves partial response; objective response rate among first-relapse ewing patients treated with seclidemstat, topotecan and cyclophosphamide reaches 60% additional ewing sarcoma patient in company's phase 1/2 sarcoma trial achieves partial response; objective response rate among first-relapse ewing patients treated with seclidemstat, topotecan and cyclophosphamide reaches 60%
2023-11-07 08:30:00 - Press Release
Salarius Completes Fda Type B Meeting For Seclidemstat Ewing Sarcoma Development Program
Fda briefing included new ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months
2023-08-10 16:05:00 - Press Release
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides A Business Update
Fda removed partial clinical hold for ewing sarcoma phase 1/2 study with seclidemstat sp-3164 targeted protein degrader received investigational new drug clearance from fda company to explore strategic alternatives and implement measures to extend its resources houston, aug. 10, 2023 (globe newswire) -- salarius pharmaceuticals, inc. (nasdaq: slrx), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended june 30, 2023 and provided a business update. financial and business highlights cash and cash equivalents were $11...
2023-07-11 08:30:00 - Press Release
Salarius Pharmaceuticals Receives Fda Clearance Of Sp-3164 Investigational New Drug Application To Begin A Phase 1 Clinical Trial In Relapsed/refractory Non-hodgkin Lymphoma Patients
The trial will assess the safety and preliminary efficacy of salarius' novel targeted protein degrader sp-3164; patient dosing expected to begin in 2h 2023
Latest News
2023-05-09 08:17:00 - Market Watch
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation.
2023-04-04 16:02:00 - GlobeNewsWire
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.
2023-01-19 08:30:00 - GlobeNewsWire
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
2022-10-19 08:30:00 - GlobeNewsWire
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius' director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiesteban's presentation, titled “Development of SP-3164, a Cereblon-Binding Molecular Glue,” will be delivered at 5:30 p.m. local time on October 26th.
2022-09-20 12:00:00 - GlobeNewsWire
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that management will present at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29th in New York City at the Sofitel Hotel. David Arthur, chief executive officer, will deliver a corporate presentation and participate in a “fireside chat” at 10:30 a.m. Eastern time. In addition to Mr. Arthur, other management team members will be available for one-on-one meetings. Please contact Ladenburg Thalmann to schedule a meeting.
2022-08-08 14:54:12 - Seeking Alpha
Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations David Arthur - Director and CEO Mark Rosenblum - Chief Financial Officer Dr. Daniela Santiesteban - Director, Protein Degradation, Development Conference Call Participants Ahu Demir - Ladenburg Operator Welcome to the Salarius Pharmaceuticals Second Quarter 2022 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
2022-08-02 10:07:49 - Proactive Investors
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.
2022-07-29 09:15:00 - GlobeNewsWire
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET
2022-05-18 16:10:00 - GlobeNewsWire
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will be virtually presenting at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
2022-05-12 21:32:13 - Seeking Alpha
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Arthur - Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director, Corporate Development Conference Call Participants Ahu Demir - Ladenburg Hunter Diamond - Diamond Equity Operator Good day, and thank you for standing by. Welcome to the First Quarter 2022 Salarius Pharmaceuticals Earnings Conference Call and Webcast.